Graft-versus-host Disease
📧 Sign up to get email alerts when something new happens for Graft-versus-host Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-04-16Clinical Trial Update: hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation [Phase 1]
A Phase 1 clinical trial evaluating hAESCs to prevent acute graft-versus-host disease after hematopoietic stem cell transplantation has been…
-
CLINICAL_TRIALS withdrawal · 2026-02-12Clinical Trial Update: Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy [Phase 2]
A Phase 2 trial evaluating the safety and efficacy of oral belumosudil in chronic graft-versus-host disease in diverse participants has been…
-
CLINICAL_TRIALS withdrawal · 2025-11-10Clinical Trial Update: Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias [Phase 2]
An extension study of fostamatinib (Syk inhibitor) for posttransplant immune-mediated cytopenias has been withdrawn, including autoimmune he…
-
CLINICAL_TRIALS withdrawal · 2025-09-22Clinical Trial Update: 5-Azacytidine With Steroids for Gastrointestinal GVHD (5-AZA FOR GVHD) [EARLY_Phase 1]
A Baylor College of Medicine-sponsored EARLY Phase 1 trial evaluating 5-Azacytidine with steroids for gastrointestinal graft-versus-host dis…
-
CLINICAL_TRIALS withdrawal · 2025-07-14Clinical Trial Update: TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant [NA]
A clinical trial evaluating TCRαβ/CD19-depleted stem cell grafts for transplantation has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-01-29Clinical Trial Update: Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Markers in Graft-Versus-Host Disease
A clinical trial investigating correlations between serum biomarkers and GVHD-related endothelial damage has been withdrawn. The study recor…
-
CLINICAL_TRIALS withdrawal · 2025-01-07Clinical Trial Update: Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD [Phase 2]
A Phase 2 trial evaluating extracorporeal photopheresis in combination with mesenchymal stem cell infusion for graft-versus-host disease has…
-
CLINICAL_TRIALS withdrawal · 2024-07-23Clinical Trial Update: Electron Beam Radiotherapy for the Treatment of Refractory Sclerodermatous Chronic Graft Versus Host Disease [EARLY_Phase 1]
The EARLY Phase 1 trial of Electron Beam Radiotherapy for refractory sclerodermatous chronic graft-versus-host disease (NCT05515692) has bee…
-
CLINICAL_TRIALS withdrawal · 2022-01-05Clinical Trial Update: Evaluation of Dextenza in Patients With Ocular GVHD and Effects on Ocular Surface Disease Outcomes [Phase 4]
Phase 4 trial evaluating Dextenza for ocular GVHD was withdrawn.
-
EMA withdrawal · 2020-02-14EMA Withdrawn: Zalmoxis (allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)) — MolMed SpA
The EMA withdrew Zalmoxis, a gene-modified allogeneic T cell product for hematopoietic stem cell transplantation and graft-versus-host disea…
-
CLINICAL_TRIALS withdrawal · 2020-01-03Clinical Trial Update: Bone Marrow Transplantation in Treating Patients With Leukemia [Phase 3]
A Phase 3 clinical trial evaluating bone marrow transplantation for leukemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-12-02Clinical Trial Update: Treg Cells for AGVHD in Non-myeloablative UCB Transplant [Phase 2]
A Phase 2 clinical trial investigating regulatory T cells to prevent acute graft-versus-host disease in non-myeloablative umbilical cord blo…
-
CLINICAL_TRIALS withdrawal · 2017-10-11Clinical Trial Update: MicroRNAs as Diagnostic and Predictive Biomarkers for Acute Graft Versus Host Disease
The clinical trial evaluating microRNAs as diagnostic and predictive biomarkers for acute graft-versus-host disease has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-08-28Clinical Trial Update: Safety and Efficacy of Autologous PRP and PPP Eye Drops in the Treatment of Ocular GVHD [Phase 1]
A Phase 1 trial evaluating autologous PRP and PPP eye drops for ocular graft-versus-host disease has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-11-21Clinical Trial Update: CliniMACS® CD34+ Reagent System for Expanded Access Use
This clinical trial update states that expanded-access use of the CliniMACS CD34+ Reagent System is no longer available.
-
EMA withdrawal · 2016-07-22EMA Application withdrawn: Begedina (begelomab) — Adienne S.r.l. S.U.
EMA withdrew the application for Begedina (begelomab) by Adienne S.r.l. S.U. for graft-versus-host disease/Hematopoietic Stem Cell Transplan…
-
CLINICAL_TRIALS withdrawal · 2016-05-06Clinical Trial Update: Tocilizumab for Chronic Graft-versus-Host Disease Treatment [Phase 2]
A Phase 2 clinical trial of tocilizumab for chronic graft-versus-host disease has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-04-25Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Neihulizumab vs "Conventional Treatment" to Treat Sr-aGvHD [Phase 2]
A Phase 2 trial evaluating neihulizumab for steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic cell transplan…
-
CLINICAL_TRIALS withdrawal · 2015-03-06Clinical Trial Update: Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant [Phase 1, Phase 2]
A Phase 1/2 clinical trial on preventing graft-versus-host disease in patients with hematologic malignancies undergoing bone marrow transpla…
-
CLINICAL_TRIALS withdrawal · 2015-03-02Clinical Trial Update: Lymphocyte Profiles and Activation Status in Patients With Graft-Versus-Host Disease
A clinical trial examining lymphocyte profiles and activation in patients with graft-versus-host disease has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2014-12-04Clinical Trial Update: OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies [Phase 2]
A Phase 2 clinical trial (OTI-010) evaluating prophylaxis against graft-versus-host disease in patients undergoing donor peripheral blood st…
-
CLINICAL_TRIALS withdrawal · 2013-10-16Clinical Trial Update: Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease [Phase 2]
A Phase 2 trial evaluating Pentostatin, Cyclophosphamide, and Rituximab for poor-prognosis chronic graft-versus-host disease has been withdr…
-
CLINICAL_TRIALS withdrawal · 2013-05-14Clinical Trial Update: Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant
A clinical trial evaluating chronic graft-versus-host disease after allogeneic donor stem cell transplantation in cancer patients has been t…
-
CLINICAL_TRIALS withdrawal · 2013-02-13Clinical Trial Update: A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease [Phase 2]
Phase 2 trial of panobinostat (LBH589) as second-line therapy for chronic graft-versus-host disease has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-07-09Clinical Trial Update: Rituximab for GVHD [Phase 2]
Phase 2 trial of Rituximab for graft-versus-host disease has been withdrawn.